Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1944 1
1946 1
1947 1
1950 1
1956 1
1959 1
1960 1
1965 1
1967 1
1969 2
1971 2
1972 6
1974 4
1975 2
1976 3
1977 2
1979 3
1980 2
1981 2
1982 1
1985 3
1989 3
1993 1
1994 1
1995 1
1997 2
1998 5
1999 3
2000 5
2001 2
2002 4
2003 3
2004 3
2005 3
2006 8
2007 7
2008 11
2009 7
2010 14
2011 18
2012 21
2013 10
2014 16
2015 16
2016 17
2017 22
2018 22
2019 18
2020 26
2021 33
2022 25
2023 25
2024 28
2025 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

403 results

Results by year

Filters applied: . Clear all
Page 1
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Reply.
Manuel MR, Francisco M. Manuel MR, et al. AJNR Am J Neuroradiol. 2024 Jul 8;45(7):E21. doi: 10.3174/ajnr.A8341. AJNR Am J Neuroradiol. 2024. PMID: 38902007 Free PMC article. No abstract available.
Ctenophores: an evolutionary-developmental perspective.
Jager M, Manuel M. Jager M, et al. Among authors: manuel m. Curr Opin Genet Dev. 2016 Aug;39:85-92. doi: 10.1016/j.gde.2016.05.020. Epub 2016 Jun 25. Curr Opin Genet Dev. 2016. PMID: 27351593 Review.
Ghost admixture in eastern gorillas.
Pawar H, Rymbekova A, Cuadros-Espinoza S, Huang X, de Manuel M, van der Valk T, Lobon I, Alvarez-Estape M, Haber M, Dolgova O, Han S, Esteller-Cucala P, Juan D, Ayub Q, Bautista R, Kelley JL, Cornejo OE, Lao O, Andrés AM, Guschanski K, Ssebide B, Cranfield M, Tyler-Smith C, Xue Y, Prado-Martinez J, Marques-Bonet T, Kuhlwilm M. Pawar H, et al. Among authors: de manuel m. Nat Ecol Evol. 2023 Sep;7(9):1503-1514. doi: 10.1038/s41559-023-02145-2. Epub 2023 Jul 27. Nat Ecol Evol. 2023. PMID: 37500909 Free PMC article.
Targeting regulatory T cells.
Ménétrier-Caux C, Curiel T, Faget J, Manuel M, Caux C, Zou W. Ménétrier-Caux C, et al. Among authors: manuel m. Target Oncol. 2012 Mar;7(1):15-28. doi: 10.1007/s11523-012-0208-y. Epub 2012 Feb 12. Target Oncol. 2012. PMID: 22327882 Review.
Mechanical Thrombectomy Access in Africa: A Mission Thrombectomy Study Subanalysis.
Alejo G, Prasad S, Otite FO, Jones EM, Yavagal DR, Ortega-Gutierrez S, Lamou EGB, Desai SM, Asif KS, Gebreyohanns M; Global Executive Committee of the MT-GLASS Study. Alejo G, et al. Stroke. 2025 May;56(5):e130-e132. doi: 10.1161/STROKEAHA.124.047825. Epub 2025 Apr 28. Stroke. 2025. PMID: 40294166 No abstract available.
Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes.
Smith EE, Shoamanesh A, Xu L, Heenan L, Saad F, Colorado P, Chen CH, Lemmens R, De Marchis GM, Caso V, Masjuan J, Hirano T, Milanov I, Campbell BCV, Mas JL, Connolly SJ, Mundl H, Hart RG; PACIFIC-Stroke Steering Committee and Investigators. Smith EE, et al. Stroke. 2024 Feb;55(2):392-402. doi: 10.1161/STROKEAHA.123.043198. Epub 2024 Jan 4. Stroke. 2024. PMID: 38174569 Clinical Trial.
403 results